ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced that it has completed the sale of its European operations to Incyte Corporation and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Management Comments Mergers and Acquisitions Special Reports

ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig®June 2, 2016 7:35 AM Form 4 ARIAD PHARMACEUTICALS For: May 31 Filed by: Herron Jennifer LynJune 1, 2016 4:54 PM Form 3 ARIAD PHARMACEUTICALS For: May 31 Filed by: Herron Jennifer LynJune 1, 2016 4:53 PM Incyte (INCY) Europe Granted Exclusive Iclusig Development, Commercialization Rights in EU, Additional Countries (ARIA)June 1, 2016 4:13 PM ARIAD to Present at the Jefferies 2016 Global Healthcare ConferenceJune 1, 2016 7:35 AM Notable put flow in option market on May 31June 1, 2016 6:37 AM Ariad Pharmaceuticals (ARIA) July calls active into American Society of Clinical Oncology (ASCO)May 31, 2016 3:35 PM Unusual call and put flow in option market on May 27May 31, 2016 7:49 AM ARIAD Pharma (ARIA) Commences AP32788 Phase 1/2 in NSCLCMay 31, 2016 7:41 AM